US9212182, 477::US9212182, 478

ID: ALA3945969

Chembl Id: CHEMBL3945969

Cas Number: 1641574-26-6

PubChem CID: 117737142

Max Phase: Preclinical

Molecular Formula: C25H16ClF2N3O5S

Molecular Weight: 543.94

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COc1cc(-c2cc(F)cc(Cl)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21

Standard InChI:  InChI=1S/C25H16ClF2N3O5S/c1-35-23-12-19(15-8-16(26)11-17(27)9-15)20(28)13-22(23)31-21-4-3-18(10-14(21)2-5-25(31)32)37(33,34)30-24-6-7-36-29-24/h2-13H,1H3,(H,29,30)

Standard InChI Key:  HXQNEKJQBGXFAG-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA3945969

   1-[4-(3-chloro-5-fluorophenyl)-5-fluoro-2-methoxyphenyl]-N-(1,2-oxazol-3-yl)-2-oxoquinoline-6-sulfonamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 543.94

Molecular Weight (Monoisotopic): 543.0467

AlogP: 5.39

#Rotatable Bonds: 6

Polar Surface Area: 103.43

Molecular Species: ACID

HBA: 7

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 5.83

CX Basic pKa: ┄

CX LogP: 4.94

CX LogD: 4.08

Aromatic Rings: 5

Heavy Atoms: 37

QED Weighted: 0.31

Np Likeness Score: -1.54

References

1.  (2015)  Bicyclic sulfonamide compounds as sodium channel inhibitors, 

2. Mulcahy JV, Pajouhesh H, Beckley JT, Delwig A, Du Bois J, Hunter JC..  (2019)  Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na_V1.7.,  62  (19): [PMID:31012583] [10.1021/acs.jmedchem.8b01906]

3. Mulcahy JV, Pajouhesh H, Beckley JT, Delwig A, Du Bois J, Hunter JC..  (2019)  Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na_V1.7.,  62  (19): [PMID:31012583] [10.1021/acs.jmedchem.8b01906]

4. Kitano Y, Shinozuka T..  (2022)  Inhibition of Na_V1.7: the possibility of ideal analgesics.,  13  (8.0): [PMID:36092147] [10.1039/d2md00081d]

5. Glunz PW..  (2018)  Recent encounters with atropisomerism in drug discovery.,  28  (2.0): [PMID:29223590] [10.1016/j.bmcl.2017.11.050]

6. Glunz PW..  (2018)  Recent encounters with atropisomerism in drug discovery.,  28  (2.0): [PMID:29223590] [10.1016/j.bmcl.2017.11.050]

Source

Source(2):

• Scientific Literature
• BindingDB Database